Eagle Pharmaceuticals, Inc. (EGRX) Balance Sheet
EGRX balance sheet, 2022
December 31, 2022 · U.S. dollars$406.2M assets = $172.6M liabilities + $233.6M equity
Both columns are drawn to the same scale: what EGRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
EGRX financial health
Descriptive bands, not a rating. Fiscal 2022.
EGRX balance sheet trends, 2013–2022
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $18.1M2013 | $406.2M2022 | +41.3%/yr | |
| Total liabilities | $16.0M2013 | $172.6M2022 | +30.2%/yr | |
| Shareholders’ equity | $2.1M2013 | $233.6M2022 | +69.2%/yr | |
| Cash & short-term investments | $10.5M2013 | $55.3M2022 | +20.3%/yr | |
| Total debt | $4.8M2013 | $67.8M2022 | +34.3%/yr | |
| Net cash (debt) | $5.7M2013 | −$12.5M2022 | −$18.2M | |
| Working capital | $3.1M2013 | $77.7M2022 | +$74.5M | |
| Book value per share | $0.192013 | $17.882022 | +65.3%/yr | |
| Current ratio | 1.222013 | 1.702022 | +0.48 | |
| Debt / equity | 2.322013 | 0.292022 | −2.03 | |
| Shares outstanding | 10.6M2013 | 13.1M2022 | +2.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
EGRX assets
EGRX liabilities and equity
EGRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
EGRX balance sheet
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $55.3M | $97.7M | $103.2M | $109.8M | $78.8M | $114.7M | $52.8M | $79.1M | $42.7M | $10.5M |
| Cash & equivalents | $55.3M | $97.7M | $103.2M | $109.8M | $78.8M | $114.7M | $52.8M | $79.1M | $22.7M | $10.5M |
| Short-term investments | — | $5.0M | — | — | — | $0 | $0 | $0 | $20.0M | — |
| Receivables | $73.4M | $41.5M | $51.1M | $48.0M | $66.5M | $53.8M | $42.2M | $26.3M | $7.3M | $5.1M |
| Inventory | $47.8M | $21.9M | $8.1M | $6.6M | $8.3M | $5.1M | $2.7M | $15.0M | $1.3M | $1.9M |
| Other current assets | $12.2M | $11.5M | $3.7M | $15.1M | $10.3M | $15.1M | $11.4M | $1.9M | $1.7M | $32,038 |
| Total current assets | $188.8M | $172.6M | $166.1M | $179.4M | $163.8M | $188.7M | $109.1M | $122.3M | $53.0M | $17.5M |
| Property, plant & equipment (net) | $1.2M | $1.6M | $2.1M | $2.2M | $2.4M | $6.8M | $3.3M | $2.2M | $344,000 | $402,286 |
| Goodwill & intangible assets | $163.4M | $50.4M | $52.7M | $55.3M | $57.8M | $63.1M | $72.4M | $0 | $73.1M | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $52.9M | $29.1M | $32.4M | $17.6M | $14.5M | $11.5M | $28.8M | $143,000 | $0 | $217,927 |
| Total assets | $406.2M | $253.7M | $253.2M | $254.6M | $238.6M | $270.1M | $213.6M | $124.6M | $53.4M | $18.1M |
| Liabilities | ||||||||||
| Accounts payable | $19.0M | $16.4M | $6.3M | $5.5M | $9.9M | $12.0M | $14.7M | $3.9M | $4.1M | $1.2M |
| Short-term debt | $7.8M | $26.9M | $9.1M | $5.0M | $6.2M | $4.9M | — | $86,000 | $9.2M | $3.1M |
| Deferred revenue | — | $25.4M | $20.7M | $26.1M | $21.7M | $15.4M | — | $6.0M | $6.6M | $10.0M |
| Total current liabilities | $111.1M | $74.4M | $38.1M | $38.8M | $39.7M | $47.3M | $40.2M | $34.3M | $20.3M | $14.3M |
| Long-term debt | $56.2M | $0 | $25.1M | $33.6M | $38.2M | $42.9M | $0 | $0 | $0 | $1.7M |
| Lease obligations | $5.3M | $4.2M | $4.0M | $3.0M | — | — | — | — | — | — |
| Other long-term liabilities | $5.3M | $2.9M | $4.0M | $3.0M | $0 | $709,000 | $22.1M | $9.9M | $10.6M | $0 |
| Total liabilities | $172.6M | $77.3M | $67.2M | $75.4M | $77.8M | $90.9M | $62.3M | $34.3M | $20.3M | $16.0M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $18,000 | $17,000 | $17,000 | $17,000 | $17,000 | $16,000 | $16,000 | $15,000 | $14,000 | $3,048 |
| Retained earnings (deficit) | $111.5M | $75.9M | $84.5M | $72.5M | $58.2M | $26.3M | −$25.7M | −$107.1M | −$104.2M | −$102.1M |
| Treasury stock | −$243.1M | −$225.1M | −$203.9M | −$171.9M | −$153.9M | −$80.8M | −$37.0M | $0 | $0 | — |
| Accumulated other comprehensive income | −$1.1M | −$94,000 | $0 | $0 | $0 | $0 | $0 | −$865,000 | $0 | −$90.0M |
| Minority interest | — | — | — | — | — | $0 | $0 | $0 | $0 | — |
| Total shareholders' equity | $233.6M | $176.5M | $186.0M | $179.2M | $160.8M | $179.1M | $151.2M | $90.3M | $33.1M | $2.1M |
| Key figures | ||||||||||
| Total debt | $67.8M | $29.8M | $38.2M | $38.6M | $44.4M | $47.8M | — | $86,000 | $9.2M | $4.8M |
| Net cash (debt) | −$12.5M | $67.8M | $64.9M | $71.2M | $34.4M | $66.9M | — | $79.0M | $33.5M | $5.7M |
| Working capital | $77.7M | $98.2M | $128.0M | $140.6M | $124.2M | $141.4M | $68.9M | $88.0M | $32.7M | $3.1M |
| Tangible book value | $70.2M | $126.0M | $133.4M | $123.8M | $102.9M | $116.1M | $78.9M | $90.3M | −$40.0M | $2.1M |
| Book value per share | $17.88 | $13.52 | $13.51 | $12.67 | $10.52 | $11.26 | $9.20 | $5.56 | $3.32 | $0.19 |
| Shares outstanding | 13.1M | 13.1M | 13.8M | 14.1M | 15.3M | 15.9M | 16.4M | 16.3M | 10.0M | 10.6M |
| Current ratio | 1.70 | 2.32 | 4.36 | 4.62 | 4.13 | 3.99 | 2.71 | 3.57 | 2.61 | 1.22 |
| Quick ratio | 1.16 | 1.87 | 4.05 | 4.06 | 3.66 | 3.56 | 2.36 | 3.07 | 2.46 | 1.09 |
| Debt / equity | 0.29 | 0.17 | 0.21 | 0.22 | 0.28 | 0.27 | — | 0.00 | 0.28 | 2.32 |
| Equity / assets | 57.5% | 69.5% | 73.5% | 70.4% | 67.4% | 66.3% | 70.8% | 72.5% | 62.0% | 11.3% |
| Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | Mar '21 | Dec '20 | Sep '20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $15.4M | $21.9M | $55.3M | $15.4M | $36.6M | $69.5M | $97.7M | $99.7M | $108.7M | $105.2M | $103.2M | $89.7M |
| Cash & equivalents | $15.4M | $21.9M | $55.3M | $15.4M | $36.6M | $69.5M | $97.7M | $99.7M | $108.7M | $105.2M | $103.2M | $89.7M |
| Short-term investments | — | — | — | — | $5.7M | $5.5M | $5.0M | $4.3M | — | — | — | — |
| Receivables | $116.3M | $116.0M | $73.4M | $97.9M | $87.4M | $136.8M | $41.5M | $51.6M | $52.7M | $44.9M | $51.1M | $57.2M |
| Inventory | $42.5M | $44.1M | $47.8M | $63.9M | $57.7M | $24.8M | $21.9M | $9.3M | $8.3M | $6.9M | $8.1M | $6.6M |
| Other current assets | $13.1M | $10.4M | $12.2M | $7.9M | $12.8M | $9.0M | $11.5M | $11.0M | $5.8M | $7.0M | $3.7M | $10.3M |
| Total current assets | $187.2M | $192.5M | $188.8M | $185.0M | $194.5M | $240.2M | $172.6M | $171.7M | $175.5M | $164.0M | $166.1M | $163.8M |
| Property, plant & equipment (net) | $1.0M | $1.1M | $1.2M | $1.3M | $1.5M | $1.6M | $1.6M | $1.8M | $2.0M | $2.3M | $2.1M | $2.1M |
| Goodwill & intangible assets | $152.4M | $157.9M | $163.4M | $150.6M | $155.5M | $49.7M | $50.4M | $50.5M | $51.2M | $52.0M | $52.7M | $53.3M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $64.1M | $62.7M | $52.9M | $53.1M | $30.3M | $28.7M | $29.1M | $32.2M | $35.5M | $41.8M | $32.4M | $28.9M |
| Total assets | $404.8M | $414.2M | $406.2M | $390.1M | $381.8M | $320.2M | $253.7M | $256.3M | $264.2M | $260.0M | $253.2M | $248.2M |
| Liabilities | ||||||||||||
| Accounts payable | $15.8M | $17.1M | $19.0M | $13.2M | $20.0M | $14.5M | $16.4M | $12.7M | $11.1M | $12.6M | $6.3M | $13.1M |
| Short-term debt | $9.7M | $9.1M | $7.8M | $36.5M | $23.3M | $25.1M | $26.9M | $9.2M | $9.2M | $9.1M | $9.1M | $9.1M |
| Deferred revenue | $60.0M | — | — | — | $58.3M | — | $25.4M | — | — | — | $20.7M | — |
| Total current liabilities | $86.6M | $97.8M | $111.1M | $121.8M | $109.0M | $101.6M | $74.4M | $48.4M | $44.7M | $42.0M | $38.1M | $45.5M |
| Long-term debt | $61.9M | $68.8M | $56.2M | $26.4M | $28.0M | $0 | $0 | $19.5M | $21.4M | $23.3M | $25.1M | $27.0M |
| Lease obligations | $1.4M | $1.6M | $5.3M | $3.4M | $3.7M | $3.9M | $4.2M | $4.2M | $4.5M | $4.8M | $4.0M | $4.0M |
| Other long-term liabilities | $4.3M | $4.7M | $5.3M | $6.4M | $6.8M | $2.6M | $2.9M | $3.0M | $3.4M | $3.7M | $4.0M | $2.8M |
| Total liabilities | $152.8M | $171.3M | $172.6M | $154.7M | $143.8M | $104.2M | $77.3M | $71.0M | $69.4M | $68.9M | $67.2M | $75.4M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $18,000 | $18,000 | $18,000 | $18,000 | $18,000 | $17,000 | $17,000 | $17,000 | $17,000 | $17,000 | $17,000 | $17,000 |
| Retained earnings (deficit) | $122.4M | $117.3M | $111.5M | $107.0M | $110.5M | $119.9M | $75.9M | $82.1M | $87.7M | $84.1M | $84.5M | $76.4M |
| Treasury stock | — | — | −$243.1M | −$243.1M | −$233.2M | −$233.2M | −$225.1M | −$216.5M | −$208.2M | −$205.3M | −$203.9M | −$199.9M |
| Accumulated other comprehensive income | −$1.1M | −$1.1M | −$1.1M | $9.4M | $2.3M | $418,000 | −$94,000 | −$882,000 | −$904,000 | $0 | $0 | $0 |
| Total shareholders' equity | $252.0M | $242.8M | $233.6M | $235.4M | $238.0M | $216.0M | $176.5M | $185.3M | $194.8M | $191.1M | $186.0M | $172.8M |
| Key figures | ||||||||||||
| Total debt | $71.6M | $76.3M | $62.5M | $61.4M | $53.6M | $27.6M | $25.6M | $31.7M | $33.9M | $36.1M | $37.1M | $39.0M |
| Net cash (debt) | −$56.3M | −$54.4M | −$7.1M | −$46.0M | −$17.0M | $41.9M | $72.1M | $68.0M | $74.8M | $69.2M | $66.1M | $50.7M |
| Working capital | $100.6M | $94.7M | $77.7M | $63.2M | $85.5M | $138.5M | $98.2M | $123.3M | $130.8M | $122.0M | $128.0M | $118.3M |
| Tangible book value | $99.6M | $84.9M | $70.2M | $84.8M | $82.5M | $166.3M | $126.0M | $134.8M | $143.6M | $139.1M | $133.4M | $119.5M |
| Book value per share | $19.16 | $18.46 | $17.80 | $17.88 | $18.54 | $16.73 | $13.68 | $14.17 | $14.69 | $14.62 | $13.51 | $12.53 |
| Shares outstanding | 13.2M | 13.2M | 13.1M | 13.2M | 12.8M | 12.9M | 12.9M | 13.1M | 13.3M | 13.1M | 13.8M | 13.8M |
| Current ratio | 2.16 | 1.97 | 1.70 | 1.52 | 1.78 | 2.36 | 2.32 | 3.55 | 3.93 | 3.91 | 4.36 | 3.60 |
| Quick ratio | 1.52 | 1.41 | 1.16 | 0.93 | 1.14 | 2.03 | 1.87 | 3.13 | 3.61 | 3.58 | 4.05 | 3.23 |
| Debt / equity | 0.28 | 0.31 | 0.27 | 0.26 | 0.23 | 0.13 | 0.15 | 0.17 | 0.17 | 0.19 | 0.20 | 0.23 |
| Equity / assets | 62.3% | 58.6% | 57.5% | 60.3% | 62.3% | 67.5% | 69.5% | 72.3% | 73.7% | 73.5% | 73.5% | 69.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 23, 2023); data from EODHD.
EGRX financial position
At the end of fiscal 2022 (December 31, 2022), Eagle Pharmaceuticals had total assets of $406.2 million (up 60.1% from a year earlier), total liabilities of $172.6 million and shareholders' equity of $233.6 million. It held $55.3 million in cash and short-term investments against $67.8 million of debt, net debt of $12.5 million. Its current ratio was 1.70. In the latest quarter (ended June 30, 2023) total assets were $404.8 million and equity $252.0 million.
Related: EGRX income statement, EGRX cash flow statement, EGRX key metrics. See the EGRX stock overview for the latest quote and news.
EGRX balance sheet FAQ
What are Eagle Pharmaceuticals's total assets?
Eagle Pharmaceuticals reported total assets of $406.2 million at the end of fiscal 2022 (December 31, 2022), compared with $253.7 million a year earlier.
How much debt does Eagle Pharmaceuticals have?
Eagle Pharmaceuticals had $67.8 million of total debt at the end of fiscal 2022, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.29.
How much cash does Eagle Pharmaceuticals have?
Eagle Pharmaceuticals held $55.3 million in cash and short-term investments at the end of fiscal 2022; with $67.8 million of debt that is net debt of $12.5 million.
What is Eagle Pharmaceuticals's book value?
Eagle Pharmaceuticals's shareholders' equity (book value) was $233.6 million at the end of fiscal 2022, or $17.88 per share.
What is Eagle Pharmaceuticals's current ratio?
Eagle Pharmaceuticals had current assets of $188.8 million and current liabilities of $111.1 million, a current ratio of 1.70 (it can cover its short-term obligations).
How much goodwill does Eagle Pharmaceuticals have?
Eagle Pharmaceuticals carried $163.4 million of goodwill and intangible assets, 40.2% of total assets, at the end of fiscal 2022.